Terms: = Kidney tumors AND MITF, WS2A, ENSG00000187098, 4286 AND Prognosis
9 results:
1. Incidental Detection of
Repetto F; Sirohi D; Greipp P; Mahlow J
Int J Surg Pathol; 2024 May; 32(3):551-555. PubMed ID: 37394760
[No Abstract] [Full Text] [Related]
2. Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression.
Kammerer-Jacquet SF; Gandon C; Dugay F; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Leroy X; Aubert S; Vermaut C; Escande F; Verkarre V; Compérat E; Ambrosetti D; Pedeutour F; Belaud-Rotureau MA; Rioux-Leclercq N;
Histopathology; 2022 Aug; 81(2):228-238. PubMed ID: 35562857
[TBL] [Abstract] [Full Text] [Related]
3. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K; Hes O; Williamson SR; Adeniran AJ; Agaimy A; Alaghehbandan R; Amin MB; Argani P; Chen YB; Cheng L; Epstein JI; Cheville JC; Comperat E; da Cunha IW; Gordetsky JB; Gupta S; He H; Hirsch MS; Humphrey PA; Kapur P; Kojima F; Lopez JI; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Menon S; Netto GJ; Przybycin CG; Rao P; Rao Q; Reuter VE; Saleeb RM; Shah RB; Smith SC; Tickoo S; Tretiakova MS; True L; Verkarre V; Wobker SE; Zhou M; Gill AJ
Mod Pathol; 2021 Jul; 34(7):1392-1424. PubMed ID: 33664427
[TBL] [Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitors in mitf family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
[TBL] [Abstract] [Full Text] [Related]
5. Xp11 Translocation Renal Cell Carcinoma and the Mesenchymal Counterparts: An Evolving Concept with Novel Insights on Clinicopathologic Features, prognosis, Treatment, and Classification.
Wang XT; Xia QY; Zhou XJ; Rao Q
Crit Rev Oncog; 2017; 22(5-6):481-497. PubMed ID: 29604926
[TBL] [Abstract] [Full Text] [Related]
6. Oncotargets in different renal cancer subtypes.
Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A
Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751
[TBL] [Abstract] [Full Text] [Related]
7. Renal cell carcinoma with mitf/TFE3 translocation in children: report of a case at the stage of lymph node involvement.
Fall B; Sarr A; Sow Y; Diao B
Afr J Paediatr Surg; 2011; 8(3):317-9. PubMed ID: 22248899
[TBL] [Abstract] [Full Text] [Related]
8. [Renal carcinoma associated with mitf/TFE translocation: report of six cases in young adults].
Hintzy MC; Camparo P; Vasiliu V; Peyromaure M; Vieillefond A
Prog Urol; 2008 May; 18(5):275-80. PubMed ID: 18538271
[TBL] [Abstract] [Full Text] [Related]
9. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
Geller JI; Argani P; Adeniran A; Hampton E; De Marzo A; Hicks J; Collins MH
Cancer; 2008 Apr; 112(7):1607-16. PubMed ID: 18278810
[TBL] [Abstract] [Full Text] [Related]
